1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (1087)
  2. Meeting Abstract (890)
  3. Review (52)
  4. Book Section (46)
  5. Editorial (35)
  6. Guidelines (21)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Gynecologic Medicine Service (2146)
  2. Solid Tumor Oncology Division (2146)
  3. Department of Medicine (2142)
  4. Gynecology Disease Management Team (1846)
  5. GDMT, Medicine (1828)
  6. Surgery (594)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (288)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (41)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (450)
  2. Gynecologic Oncology (418)
  3. International Journal of Gynecological Cancer (154)
  4. Annals of Oncology (116)
  5. Clinical Cancer Research (67)
  6. Cancer Research (55)

More Publications

Publishers
  1. Elsevier Inc. (542)
  2. American Society of Clinical Oncology (489)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (168)
  5. Oxford University Press (143)
  6. Nature Publishing Group (86)

More Publishers

Results (2146)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST)
    Meeting Abstract

    D'Adamo, D. R.; Keohan, M. L.; Carvajal, R. D.; Hensley, M. L.; Hirst, C.; Qin, L.; Antonescu, C.; Lefkowitz, R. A.; Schwartz, G. K.; Maki, R. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study
    Meeting Abstract

    Burris, H. A.; Siu, L. L.; Infante, J. R.; Wheler, J. J.; Kurkjian, C.; Opalinska, J.; Smith, D. A.; Antal, J. M.; Gauvin, J. L.; Gonzalez, T.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Feasibility and yield of offering genetic counseling to all patients with newly diagnosed high-grade epithelial ovarian cancer
    Meeting Abstract

    Arnold, A. G.; Bhatia, J.; Phillips, M. F.; Gardner, G. J.; Bell-McGuinn, K. M.; Aghajanian, C.; Barakat, R. R.; Offit, K.; Kauff, N. D.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor
    Meeting Abstract

    Banerji, U.; Aghajanian, C.; Raymond, E.; Kurzrock, R.; Blanco-Codesido, M.; Oelmann, E.; Grinsted, L.; Burke, W.; Kaye, S. B.; Naing, A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Patterns of disease relapse and progression in patients with multiple myeloma after first line therapy with autologous stem cell transplantation: Implications for patient monitoring after transplantation
    Meeting Abstract

    Zamarin, D.; Bhutani, M.; Chimento, D.; Giralt, S.; Lendvai, N.; Landau, H.; Lesokhin, A.; Chung, D.; Babu, D.; Hassoun, H.
    Blood (2011)

    Fulltext@MSK | Save
  • Genetic and functional investigation of germline JAK2 alleles that predispose to myeloproliferative neoplasms
    Meeting Abstract

    Schram, A. M.; Xu, X.; Kilpivaara, O.; Mukherjee, S.; Viny, A. D.; Guryanova, O.; Klein, R. J.; Levine, R. L.
    Blood (2011)

    Fulltext@MSK | Save
  • CON: Patients with recurrent ovarian carcinoma should not be treated with antiangiogenic agents in combination with chemotherapy
    Journal Article

    Sabbatini, P.
    Clinical Ovarian Cancer (2011)

    Fulltext@MSK | Save
  • New drugs for ovarian cancer
    Journal Article

    Bell-Mcguinn, K.; Konner, J.; Tew, W.; Spriggs, D. R.
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Journal Article

    Konner, J. A.; Grabon, D. M.; Gerst, S. R.; Iasonos, A.; Thaler, H.; Pezzulli, S. D.; Sabbatini, P. J.; Bell-Mcguinn, K. M.; Tew, W. P.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Predictors of survival in ovarian cancer brain metastases
    Meeting Abstract

    Teckie, S.; Makker, V.; Tabar, V.; Shi, W.; Zhang, Z.; Aghajanian, C.; Beal, K.
    International Journal of Radiation Oncology, Biology, Physics (2011)

    Fulltext@MSK | Save